Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
ADCLEC.syn1 CAR T cells by Takeda Pharmaceutical for Refractory Acute Myeloid Leukemia: Likelihood of Approval
ADCLEC.syn1 CAR T cells is under clinical development by Takeda Pharmaceutical and currently in Phase I for Refractory Acute Myeloid...
Data Insights
ADCLEC.syn1 CAR T cells by Takeda Pharmaceutical for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
ADCLEC.syn1 CAR T cells is under clinical development by Takeda Pharmaceutical and currently in Phase I for Relapsed Acute Myeloid...